The activation of leptin downstream effectors induced growth and motility in GBM cells, and the induced effects on GBM cancer cells were inhibited by the selective leptin antagonist as well as by the specific inhibitor of Notch signaling, suggesting that leptin/Notch crosstalk may be a potential novel target for GBM therapeutics [45]. The gene discussed is LEP; the disease is glioblastoma.